Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients

References

• 1. Luznik L, O'Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant 14(6), 641–650 (2008).
  Medline CASGoogle Scholar
• 2. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol. Blood Marrow Transplant 4(3), 157–163 (1998).
  Medline CASGoogle Scholar
• 3. Przepiorka D, Devine S, Fay J, Uberti J, Wingard J. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant 24(10), 1053–1056 (1999).
  Medline CASGoogle Scholar
• 4. Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2–3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant 54(1), 155–158 (2019).
  Medline CASGoogle Scholar
• 5. Ganetsky A, Shah A, Miano TA et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 51(4), 568–572 (2016).
  Medline CASGoogle Scholar
• 6. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077–6080 (1993).
  Medline CASGoogle Scholar
• 7. Dai Y, Hebert MF, Isoherranen N et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 34(5), 836–847 (2006).
  Medline CASGoogle Scholar
• 8. Birdwell KA, Decker B, Barbarino JM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin. Pharmacol. Ther. 98(1), 19–24 (2015).
  Medline CASGoogle Scholar
• 9. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721–726 (2010).
  Medline CASGoogle Scholar
• 10. Clinical Pharmacogenetics Implementation Consortium. CYP3A5 frequency table. https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/ (Accessed 15 May 2023).
  Google Scholar
• 11. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574–1583 (2011).
  Medline CASGoogle Scholar
• 12. Elens L, Van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383–1396 (2011).
  CASGoogle Scholar
• 13. Elens L, Capron A, Van Schaik RH et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther. Drug Monit. 35(5), 608–616 (2013).
  Medline CASGoogle Scholar
• 14. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin. Pharmacol. Ther. 102(4), 688–700 (2017).
  Medline CASGoogle Scholar
• 15. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274–286 (2011).
  MedlineGoogle Scholar
• 16. Wang D, Sadee W. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet. Genomics 26(1), 40–43 (2016).
  Medline CASGoogle Scholar
• 17. Scheibner A, Remmel R, Schladt D et al. Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination. Pharmacotherapy 38(7), e46–e52 (2018).
  Medline CASGoogle Scholar
• 18. Walker AH, Jaffe JM, Gunasegaram S et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum. Mutat. 12(4), 289 (1998).
  Medline CASGoogle Scholar
• 19. Hamadeh IS, Zhang Q, Steuerwald N et al. Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Biol. Blood Marrow Transplant 25(4), 656–663 (2019).
  Medline CASGoogle Scholar
• 20. PharmGKB. Very Important Pharmacogene: ABCB1. www.pharmgkb.org/vip/PA166170352 (Accessed 15 May 2023).
  Google Scholar
• 21. Khaled SK, Palmer JM, Herzog J et al. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol. Blood Marrow Transplant 22(2), 268–276 (2016).
  Medline CASGoogle Scholar
• 22. Onizuka M, Kunii N, Toyosaki M et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 46(8), 1113–1117 (2011).
  Medline CASGoogle Scholar
• 23. Woodahl EL, Hingorani SR, Wang J et al. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. Pharmacogenomics J. 8(4), 248–255 (2008).
  Medline CASGoogle Scholar
• 24. Yanagimachi M, Naruto T, Tanoshima R et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin. Transplant. 24(6), 855–861 (2010).
  Medline CASGoogle Scholar
• 25. Yanagisawa R, Katsuyama Y, Shigemura T et al. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant 46(1), 90–97 (2011).
  Medline CASGoogle Scholar
• 26. Pasternak AL, Zhang L, Hertz DL. CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration. Pharmacogenomics 19(6), 563–576 (2018).
  CASGoogle Scholar
• 27. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6), 825–828 (1995).
  Medline CASGoogle Scholar
• 28. Jagasia MH, Greinix HT, Arora M et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transplant 21(3), 389–401.e381 (2015).
  MedlineGoogle Scholar
• 29. Armand P, Gibson CJ, Cutler C et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120(4), 905–913 (2012).
  Medline CASGoogle Scholar
• 30. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of Statistics. 6(2), 65–70 (1979). (Wiley).
  Google Scholar
• 31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 16, 1141–1154 (1988).
  Google Scholar
• 32. Gray RJ, Fine JP. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 94(446), 496–509 (1999).
  Google Scholar
• 33. Zhu J, Patel T, Miller JA et al. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. Int. J. Mol. Sci. 21(3), 858 (2020).
  Google Scholar
• 34. Yamashita T, Fujishima N, Miura M et al. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation. Cancer Chemother. Pharmacol. 78(1), 111–118 (2016).
  Medline CASGoogle Scholar
• 35. Tacrolimus, package insert. Astellas Pharma Inc., IL, USA.
  Google Scholar
• 36. Pasternak AL, Marcath LA, Li Y et al. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy. Transplant Cell Ther. 28(1), 19.e11–19.e17 (2022).
  Google Scholar
• 37. Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51(8), 1374–1381 (2005).
  Medline CASGoogle Scholar
• 38. Suetsugu K, Mori Y, Yamamoto N et al. Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci. 20(10), 2413 (2019).
  MedlineGoogle Scholar
• 39. Iwamoto T, Monma F, Fujieda A et al. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation. Ther. Drug Monit. 37(5), 581–588 (2015).
  Medline CASGoogle Scholar
• 40. Pallet N, Jannot AS, El Bahri M et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am. J. Transplant 15(3), 800–805 (2015).
  Medline CASGoogle Scholar
• 41. Gijsen VM, Van Schaik RH, Elens L et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 14(9), 1027–1036 (2013).
  CASGoogle Scholar
• 42. Liu YY, Li C, Cui Z et al. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Gene 531(2), 476–488 (2013).
  Medline CASGoogle Scholar
• 43. Krupski MC, Bodiford A, Culos K. Tacrolimus Metabolism and Risk of Acute Graft Versus Host Disease. Blood 126(23), 1954 (2015).
  Google Scholar
• 44. Moiseev IS, Burmina EA, Muslimov AR et al. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis. Ann. Hematol. 96(6), 935–942 (2017).
  Medline CASGoogle Scholar
• 45. Sharma N, Zhao Q, Ni B et al. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. Cancers (Basel) 13(4), 613 (2021).
  Medline CASGoogle Scholar
• 46. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119(17), 3908–3916 (2012).
  Medline CASGoogle Scholar